Navigation Links
OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
Date:10/4/2010

BOTHELL, WA and VANCOUVER, Oct. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that management of OncoGenex will present at the 9th Annual BIO Investor Forum on Wednesday, October 6 at 10:30 a.m. PDT at The Palace Hotel in San Francisco, CA.

Live webcasts from this conference will be available through the Investor Relations page of the OncoGenex Web site at http://ir.oncogenex.com. Webcast replays will be available approximately two hours after the calls are completed and will be archived for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011; OGX-427 is in Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex's Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities and the timing of these activities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, uncertainties regarding our future operating results, the risk that our product candidates will not obtain the requisite regulatory approvals to commercialize or that the future sales of our product candidates may be less than expected, and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2009 and the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
2. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
3. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
4. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
5. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
6. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
7. OncoGenex Reports Third Quarter Financial Results
8. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
9. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... 27, 2016 , ... Most consumers engage with biometrics technology ... secure access, voice recognition for hands-free communication, and facial recognition to help organize ... technology today. But if they asked Joey Pritikin, Vice President of Marketing ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors in expanding ... detection. , PathSensors deploys the CANARY® test platform for the detection of ...
(Date:4/27/2016)... April 27, 2016 ReportsnReports.com ... with specific focus on US, EU, ... , to the healthcare business intelligence collection of ... Complete report on the Flow Cytometry market ... supported with 282 tables and figures is now ...
(Date:4/26/2016)... ... April 26, 2016 , ... Mr. Palmer created the ... signing the first multi-million dollar, multi-year managed services contract in the U.S. intelligence community ... join our leadership team,” said John Younger, founder of Accolo. “We are growing ...
Breaking Biology Technology:
(Date:3/11/2016)... --> --> ... Recognition Market by Technology (Pattern Recognition), by Component (Hardware, ... Type (On-Premises and Cloud), by Industry Vertical and by ... the global market is expected to grow from USD ... 2020, at a CAGR of 19.1%. , ...
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® ... and enrollment solutions, today announced the addition of ... Altus multi-factor authentication platform. New contextual ... managers to step-up security where it,s needed most ... Washington, DC . --> ...
(Date:3/2/2016)... http://www.researchandmarkets.com/research/wzwqtz/global_biometrics ... "Global Biometrics Market in Hospitality Sector 2016-2020" ... , , Global biometrics market in the ... of around 27%   --> ... addition of the  "Global Biometrics Market in ...
Breaking Biology News(10 mins):